Sodium phenylbutyrate/tauroursodeoxycholic acid

Drug Profile

Sodium phenylbutyrate/tauroursodeoxycholic acid

Alternative Names: AMX 0035; Tauroursodeoxycholic acid/sodium phenylbutyrate

Latest Information Update: 19 Jun 2017

Price : $50

At a glance

  • Originator Amylyx Pharmaceuticals
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Alzheimer's disease

Most Recent Events

  • 01 Jun 2017 Phase-II clinical trials in Amyotrophic lateral sclerosis (In adults, In the elderly) in USA (PO) (NCT03127514)
  • 19 Jan 2016 Amylyx plans a phase II trial for Amyotrophic lateral sclerosis in USA ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top